COVAXIN
BBV154
COVAXIN® - India's First
Indigenous COVID-19 Vaccine
COVAXIN®, India's indigenous COVID-19 vaccine
by Bharat Biotech is developed in collaboration with
the Indian Council of Medical Research (ICMR) -
National Institute of Virology (NIV).
The indigenous, inactivated vaccine is developed
and manufactured in Bharat Biotech's BSL-3 (Bio-
Safety Level 3) high containment facility .
The vaccine is developed using Whole -Virion
Inactivated Vero Cell derived platform technology.
Inactivated vaccines do not replicate and are
therefore unlikely to revert and cause pathological
effects. They contain dead virus, incapable of
infecting people but still able to instruct the immune
system to mount a defensive reaction against an
infection.
Why develop Inactivated Vaccine? Conventionally,
inactivated vaccines have been around for decades.
Numerous vaccines for diseases such as Seasonal
Influenza, Polio, Pertussis, Rabies, and Japanese
Encephalitis use the same technology to develop
inactivated vaccines with a safe track record of >300
million doses of supplies to date. It is the well-
established , and time -tested platform in the world of
vaccine technology.
Key Attributes:
COVAXIN® is included along with immune-potentiators,
also known as vaccine adjuvants, which are added to the
vaccine to increase and boost its immunogenicity.
It is a 2-dose vaccination regimen given 28 days apart.
It is a vaccine with no sub-zero storage, no reconstitution
requirement, and ready to use liquid presentation in multi-
dose vials, stable at 2-8oC.
Pre-clinical studies: Demonstrated strong immunogenicity
and protective efficacy in animal challenge studies
conducted in hamsters & non-human primates. For more
information about our animal study, please visit our blog
page on Non-Human Primates.
The vaccine received DCGI approval for Phase I & II
Human Clinical Trials in July, 2020.
A total of 375 subjects have been enrolled in the Phase 1
study and generated excellent safety data without any
reactogenicity. Vaccine-induced neutralizing antibody titers
were observed with two divergent SARS-CoV-2 strains.
Percentage of all the side-effects combined was only 15%
in vaccine recipients. For further information, visit our blog
page on phase 1 study.
In Phase 2 study, 380 participants of 12-65 years were
enrolled. COVAXIN® led to tolerable safety outcomes and
enhanced humoral and cell-mediated immune responses.
Know more about our phase 2 study.
A total of 25,800 subjects have been enrolled and
randomized in a 1:1 ratio to receive the vaccine and
control in a Event-Driven, randomized, double-blind,
placebo-controlled, multicentre phase 3 study.
The purpose of this study is to evaluate the efficacy, safety,
and immunogenicity of COVAXIN® in volunteers aged ≥18
years.
Of the 25,800 participants, >2400 volunteers were above
60 years of age and >4500 with comorbid conditions.
COVAXIN® demonstrated 81% interim efficacy in
preventing COVID-19 in those without prior infection after the
second dose.
COVAXIN ® effective against UK variant strain:
Analysis from the National Institute of Virology indicates
that vaccine-induced antibodies can neutralize the UK
variant strains and other heterologous strains.
Global Acceptance of COVAXIN ® :
Bharat biotech has been approached by several countries
across the world for the procurement of COVAXIN®.
Clinical trials in other countries to commence soon.
Supplies from government to government in the following
countries to take place: Mongolia, Myanmar, Sri Lanka,
Philippines, Bahrain, Oman, Maldives and Mauritius.
Bharat Biotech is a pioneering biotechnology
company known for its world-class R&D and
manufacturing capabilities. Our mission is to
deliver affordable, safe and high-quality vaccines
and bio-therapeutics that help people prevail over
diseases. We seek to lead innovation in
biotechnology in order to lead the fight against
disease with a focus on emerging markets.
! " # $ %
Q U I C K L I N KS
Overview History & Milestones
Founder's Profile Accolades
Quality Control Publications
Clinical Research Manufacturing Facilities
Partnerships HR Philosophy
Media Library Bharat in News
Press Releases Research Areas
R&D Pipeline Patents
EH&S Contact Us
O U R PRO D U C TS
Biohib Biopolio
Comvac 3 Comvac 4
Comvac 5 HNVAC
Indirab JENVAC
Revac-B mcf Revac-B+
ROTAVAC ROTAVAC 5D
Typbar Typbar TCV
SLVRGEN Biogit
Regen-D 150 Regen-D 60
© 2021 Bharat Biotech. All Rights Reserved.
Privacy Policy | Terms of Service
